IONIS PHARMACEUTICALS INC IONS

Ionis Pharmaceuticals' strongest fresh development in the supplied rail is the May 28 2026 8-K: the company said its partner GSK reported positive pivotal data for bepirovirsen, an investigational ASO for chronic hepatitis B, and that GSK anticipated first regulatory decisions in Q3 2026. That is the live product hinge in this file. It is not an approval, not a launch figure and not a revenue number, but it is a named programme with a named partner and a dated regulatory window.

Ionis is presented here as a biotechnology company whose value case rests on medicine, research spending and partner-led progress rather than a simple retail sales line. The supplied product rail points specifically to bepirovirsen and chronic hepatitis B; the financial rail shows a business still carrying material losses while holding substantial liquid resources. That is the useful tension for a normal reader: the company has scientific and regulatory events in view, but the filings still show the cost of getting there.

The latest SEC EDGAR financial facts show revenue from contracts with customers of $246.1M for the 10-Q period ending 2026-03-31, net loss attributable to parent of $92.5M, operating loss of $117.4M and diluted EPS of $0.56 negative. The same 10-Q period shows assets of $3.45B, liabilities of $2.96B, stockholders' equity attributable to parent of $491.4M, cash and cash equivalents of $173.4M and short-term investments of $1.75B. The annual 10-K period ending 2025-12-31 supplies R&D expense of $915.6M and revenues of $203.3M.

The source pack contains SEC filing routes, companyfacts and submissions data, but no chart route and no approved market-price rail beyond the Form 4 transaction ranges. That means this report can discuss filings, products, balance sheet shape and disclosed share-plan activity, but it cannot claim candle patterns, support levels, resistance levels or volume behaviour. The market mechanism here is simpler: readers are weighing a partner-driven regulatory timetable against losses, liquidity and public-company equity filing trail.

What changed most clearly is the bepirovirsen disclosure from the May 28 8-K and the cluster of June filings. The June 8 8-K records approval of an amendment to the Amended and Restated Ionis Pharmaceuticals, Inc. plan. The June 16 Form 4 rail includes Rule 10b5-1 plan language, and one filing says shares changed hands in multiple transactions across $72.68 to $73.67 and $73.735 to $74.28. A June 15 Form 144 includes the representation that there was no undisclosed material adverse information about the issuer's operations. These are not product outcomes; they are governance and disclosure signals around the equity.

The file would deepen materially with the actual regulatory decision named in the May 28 disclosure, any later Ionis or GSK release on bepirovirsen, and the next parsed quarterly filing. Until then, the evidence establishes a high-spend biotechnology story with a named chronic hepatitis B programme, a large short-term investment balance, and losses that keep the financing question close to the science.